CRUPI, EMANUELE
CRUPI, EMANUELE
Facoltà di Medicina e Chirurgia
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC)
2024-01-01 Mercinelli, C.; Raggi, D.; Cigliola, A.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Moschini, M.; Re, C.; Avesani, G.; Briganti, A.; Montorsi, F.; Ross, J. S.; Graf, R.; Pavlick, D. C.; Necchi, A.
Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
2025-01-01 Tateo, Valentina; De Jong, Joep J.; Cigliola, Antonio; Maiorano, Brigida A.; Mercinelli, Chiara; Crupi, Emanuele; Giannatempo, Patrizia; Colecchia, Maurizio; Moschini, Marco; Proudfoot, James A.; Santini, Daniele; Davicioni, Elai; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Data from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
2023-01-01 Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A.; Ross, Jeffrey S.; Raggi, Daniele; Marandino, Laura; Costa De Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study
2024-01-01 Reike, M. J.; Raggi, D.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; De Padua, T. C.; Black, P. C.; Gibb, E. A.; Necchi, A.
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC)
2024-01-01 Mercinelli, C.; Basile, G.; Raggi, D.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; Padua, T. C. D.; Colecchia, M.; Colombo, R.; Moschini, M.; Re, C.; Avesani, G.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Necchi, A.
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
2025-01-01 Tateo, V.; De Jong, J. J.; Cigliola, A.; Maiorano, B. A.; Mercinelli, C.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Proudfoot, J. A.; Santini, D.; Davicioni, E.; Briganti, A.; Montorsi, F.; Necchi, A.
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI
2024-01-01 Brembilla, G.; Basile, G.; Cosenza, M.; Giganti, F.; Del Prete, A.; Russo, T.; Pennella, R.; Lavalle, S.; Raggi, D.; Mercinelli, C.; Tateo, V.; Cigliola, A.; Patane, D.; Crupi, E.; Giannatempo, P.; Messina, A.; Calareso, G.; Martini, A.; Bandini, M.; Moschini, M.; Cardone, G.; Briganti, A.; Montorsi, F.; Necchi, A.; De Cobelli, F.
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial
2022-01-01 Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A; Ross, Jeffrey S; Raggi, Daniele; Marandino, Laura; Costa de Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC)
2024-01-01 Tateo, V.; Gibb, E.; Mercinelli, C.; Raggi, D.; Cigliola, A.; Patane, D. A.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Avesani, G.; Briganti, A.; Montorsi, F.; Santini, D.; Necchi, A.
Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials
2024-01-01 Cigliola, A.; Basile, G.; Mercinelli, C.; Raggi, D.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Colombo, R.; Avesani, G.; Re, C.; Briganti, A.; Montorsi, F.; Necchi, A.
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer
2024-01-01 Necchi, A.; Basile, G.; Gibb, E. A.; Raggi, D.; Calareso, G.; De Padua, T. C.; Patane, D.; Crupi, E.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Giannatempo, P.; Moschini, M.; Briganti, A.; Montorsi, F.; Messina, A.; Ross, J. S.; Pavlick, D.; De Cobelli, F.; Brembilla, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC) | 1-gen-2024 | Mercinelli, C.; Raggi, D.; Cigliola, A.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Moschini, M.; Re, C.; Avesani, G.; Briganti, A.; Montorsi, F.; Ross, J. S.; Graf, R.; Pavlick, D. C.; Necchi, A. | |
| Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer | 1-gen-2025 | Tateo, Valentina; De Jong, Joep J.; Cigliola, Antonio; Maiorano, Brigida A.; Mercinelli, Chiara; Crupi, Emanuele; Giannatempo, Patrizia; Colecchia, Maurizio; Moschini, Marco; Proudfoot, James A.; Santini, Daniele; Davicioni, Elai; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea | |
| Data from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial | 1-gen-2023 | Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A.; Ross, Jeffrey S.; Raggi, Daniele; Marandino, Laura; Costa De Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea | |
| Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study | 1-gen-2024 | Reike, M. J.; Raggi, D.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; De Padua, T. C.; Black, P. C.; Gibb, E. A.; Necchi, A. | |
| First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) | 1-gen-2024 | Mercinelli, C.; Basile, G.; Raggi, D.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; Padua, T. C. D.; Colecchia, M.; Colombo, R.; Moschini, M.; Re, C.; Avesani, G.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Necchi, A. | |
| Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer | 1-gen-2025 | Tateo, V.; De Jong, J. J.; Cigliola, A.; Maiorano, B. A.; Mercinelli, C.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Proudfoot, J. A.; Santini, D.; Davicioni, E.; Briganti, A.; Montorsi, F.; Necchi, A. | |
| Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI | 1-gen-2024 | Brembilla, G.; Basile, G.; Cosenza, M.; Giganti, F.; Del Prete, A.; Russo, T.; Pennella, R.; Lavalle, S.; Raggi, D.; Mercinelli, C.; Tateo, V.; Cigliola, A.; Patane, D.; Crupi, E.; Giannatempo, P.; Messina, A.; Calareso, G.; Martini, A.; Bandini, M.; Moschini, M.; Cardone, G.; Briganti, A.; Montorsi, F.; Necchi, A.; De Cobelli, F. | |
| Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial | 1-gen-2022 | Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A; Ross, Jeffrey S; Raggi, Daniele; Marandino, Laura; Costa de Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea | |
| The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC) | 1-gen-2024 | Tateo, V.; Gibb, E.; Mercinelli, C.; Raggi, D.; Cigliola, A.; Patane, D. A.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Avesani, G.; Briganti, A.; Montorsi, F.; Santini, D.; Necchi, A. | |
| Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials | 1-gen-2024 | Cigliola, A.; Basile, G.; Mercinelli, C.; Raggi, D.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Colombo, R.; Avesani, G.; Re, C.; Briganti, A.; Montorsi, F.; Necchi, A. | |
| Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer | 1-gen-2024 | Necchi, A.; Basile, G.; Gibb, E. A.; Raggi, D.; Calareso, G.; De Padua, T. C.; Patane, D.; Crupi, E.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Giannatempo, P.; Moschini, M.; Briganti, A.; Montorsi, F.; Messina, A.; Ross, J. S.; Pavlick, D.; De Cobelli, F.; Brembilla, G. |